Warburg <scp>effect‐related</scp> risk scoring model to assess clinical significance and immunity characteristics of glioblastoma

Zhang, Rong; Wang, Can; Zheng, Xiaohong; Li, Shenglan; Zhang, Weichunbai; Kang, Zhuang; Yin, Shuo; Chen, Jinyi; Chen, Feng; Li, Wenbin

doi:10.1002/cam4.6627

Cited by 4 publications

(1 citation statement)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the metabolic pathways underpinning rapid tumor growth are increasingly being recognized as viable targets for cancer therapy. Moreover, the Warburg effect can be used to assess the prognosis and microenvironment of the glioma [ 213 ].…”

Section: Proteomics and Metabolomicsmentioning

confidence: 99%

Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

Onciul,

Brehar,

Toader

et al. 2024

CIMB

View full text Add to dashboard Cite

Gliomas constitute a diverse and complex array of tumors within the central nervous system (CNS), characterized by a wide range of prognostic outcomes and responses to therapeutic interventions. This literature review endeavors to conduct a thorough investigation of gliomas, with a particular emphasis on glioblastoma (GBM), beginning with their classification and epidemiological characteristics, evaluating their relative importance within the CNS tumor spectrum. We examine the immunological context of gliomas, unveiling the intricate immune environment and its ramifications for disease progression and therapeutic strategies. Moreover, we accentuate critical developments in understanding tumor behavior, focusing on recent research breakthroughs in treatment responses and the elucidation of cellular signaling pathways. Analyzing the most novel transcriptomic studies, we investigate the variations in gene expression patterns in glioma cells, assessing the prognostic and therapeutic implications of these genetic alterations. Furthermore, the role of epigenetic modifications in the pathogenesis of gliomas is underscored, suggesting that such changes are fundamental to tumor evolution and possible therapeutic advancements. In the end, this comparative oncological analysis situates GBM within the wider context of neoplasms, delineating both distinct and shared characteristics with other types of tumors.

show abstract

Section: Proteomics and Metabolomicsmentioning

confidence: 99%

Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

Onciul,

Brehar,

Toader

et al. 2024

CIMB

View full text Add to dashboard Cite

show abstract

Combined metformin and simvastatin therapy inhibits SREBP2 maturation and alters energy metabolism in glioma

Qiao,

Wang,

Chen

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

This study aims to explore the inhibitory effects of combined metformin and simvastatin therapy on the malignant progression of glioma. The research specifically examines how the maturation of SREBP2 as a transcription factor affects the expression of GLUT1 and GLUT6 in glioma cells. Additionally, it investigates the impact of this combination therapy on the biological functions and energy metabolism of glioma cells. To assess the functions of GLUT1/6, sh-GLUT1/6 plasmids were employed. The study determined the half-maximal inhibitory concentrations (IC50) of metformin and simvastatin using the CCK-8 assay. Subsequently, the effects of these drugs on glioma metabolism, proliferation, and apoptosis were explored in vitro and in vivo, using drug concentrations significantly lower than their respective IC50 values. The impact of drug treatment on GLUT1/6 and SREBP2 expression levels was also evaluated. The study elucidated the significant impact of GLUT1/6 on glioma cell functions, resulting in decreased glucose uptake. Moreover, it unveiled the regulatory role of SREBP2 in GLUT1 and GLUT6 transcription, alongside revealing differential expression of SREBP2 precursor and mature forms within gliomas. Following combined drug therapy, GLUT1/6 expression decreased, while the precursor form of SREBP2 increased, and mature SREBP2 reduced. This dual-drug treatment effectively modulated glioma cell energy metabolism. Subsequent in vivo experiments affirmed the augmented anti-tumor efficacy of combined drug therapy. Specifically, the synergistic action of metformin and simvastatin reshaped glioma metabolism, curbed malignant proliferation, promoted apoptosis, and demonstrated superior anti-tumor effects both in vitro and in vivo compared to individual administration of metformin or simvastatin. Importantly, the combination therapy achieved these effects at lower doses, rendering it a safer treatment option.

show abstract

Differential Gene Expression Analysis Supports Dysregulation of Mitochondrial Activity as a New Perspective for Glioblastoma's Aggressiveness

Cunha de Oliveira,

Gouvea de Souza,

Bispo

et al. 2024

SSRN Journal

View full text Add to dashboard Cite

Warburg effect‐related risk scoring model to assess clinical significance and immunity characteristics of glioblastoma

Cited by 4 publications

References 58 publications

Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

Deciphering Glioblastoma: Fundamental and Novel Insights into the Biology and Therapeutic Strategies of Gliomas

Combined metformin and simvastatin therapy inhibits SREBP2 maturation and alters energy metabolism in glioma

Differential Gene Expression Analysis Supports Dysregulation of Mitochondrial Activity as a New Perspective for Glioblastoma's Aggressiveness

Contact Info

Product

Resources

About